Reconciled ClinicalTrials.gov v2 Protocol Specification
| Protocol Field | Verified Registry Value |
|---|---|
| NCT Identifier | NCT06221748 |
| Consolidated Lead Sponsor | RemeGen Co |
| Therapeutic Condition Cohort | Oncology and Hematology |
| Clinical Trial Phase | Phase II/III |
| Overall Recruitment Status | RECRUITING |
| Registered Enrollment | 90 participants (ESTIMATED) |
| Registered Start Date | 2024-02-22 |
| WhyStopped Classification | Not Stopped |
Named U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Site Profile |
|---|---|---|
| Beijing Cancer Hospital | Beijing, China | Open Hospital Dossier -> |
| The First Affiliated Hospital of Xiamen University | Xiamen, China | Open Hospital Dossier -> |
| Harbin Medical University Cancer Hospital | Harbin, China | Open Hospital Dossier -> |
| The first affiliated hospital of Zhengzhou University | Zhengzhou, China | Open Hospital Dossier -> |
Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.